+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 1Year +
All Genders
ID07440290

DETERMINE Trial Arm 07 Evaluating Dabrafenib and Trametinib in Patients of All Ages with BRAF V600 Mutation-Positive Rare and Uncommon Cancers

Led by Cancer Research UK · Updated on 2026-08-17

30

Participants Needed

27

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of two drugs, dabrafenib and trametinib, in adult, pediatric, and teenageyoung adult patients with cancers that have a specific mutation called BRAF V600. These drugs are already approved for certain cancers like melanoma, lung cancer, and glioma. The goal is to see if they are also helpful for treating other rare or uncommon cancers with this mutation. This study is part of a larger program called DETERMINE, which aims to find new treatment options for rare cancers by matching drugs to specific mutations. Participants in this trial will receive dabrafenib and trametinib given orally in doses adjusted by age and body weight. Adults take dabrafenib twice daily and trametinib once daily in 28-day cycles. Pediatric and young adult patients have dosing options based on age or weight. Treatment continues until the disease progresses, unacceptable side effects occur, or consent is withdrawn. Blood samples and biopsies will be collected for research during treatment and at the end of treatment. After treatment ends, participants will be followed up every three months for two years. Throughout the study, patients will undergo disease assessments regularly to measure response and benefit, including tumor size changes and progression-free survival. Quality of life will be monitored with surveys at baseline and during treatment cycles. Safety is closely followed, tracking any serious or unexpected side effects. The total participation may last up to two years after the last treatment dose, allowing researchers to evaluate long-term outcomes and benefits of the treatment combination in these rare cancers.

CONDITIONS

Brief Title

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Research Team

A

Aida Sarmiento Castro

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here